Heart-Saving hope for neuroendocrine cancer patients
NCT ID NCT04810091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding telotristat ethyl to standard therapy can help control carcinoid syndrome and prevent heart damage in people with advanced neuroendocrine tumors. About 79 adults with metastatic disease who are already on stable somatostatin analog therapy will take part. The main goal is to measure changes in a heart stress marker (NTproBNP) over six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.